Early symptoms that mimic common ear and sinus conditions often lead to delayed diagnosis.

The predictive variables assessed were age at EGPA diagnosis, baseline eosinophil count, history of chronic sinusitis prior to diagnosis, and glucocorticoid-treated asthma at diagnosis.

People with allergic fungal rhinosinusitis taking Dupixent saw significant improvement in congestion and sinus inflammation, ...

Doctors in Central Texas share the latest on flu strains, RSV, stomach viruses and cedar pollen as cold and allergy season ...

The FDA has approved dupilumab to treat allergic fungal rhinosinusitis in adults and children ages 6 years and older.

The FDA granted approval to dupilumab for treating patients aged 6 years and up with allergic fungal rhinosinusitis and a history of sino-nasal surgery, marking the first treatment approved for this ...

ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, ...

The approval makes Dupixent the first FDA-approved therapy for allergic fungal rhinosinusitis, supported by Phase III data showing significant improvements in sinus opacification, nasal symptoms, and ...

Dupixent (dupilumab) is now FDA-approved for adults and children aged 6 years and older with allergic fungal rhinosinusitis and prior sino-nasal surgery.

Max Nelson never let near-blindness prevent him from his passion, Nordic skiing. He was a conference champion in high school at Mahtomedi, skied for his college team, and was a ...